Analytical Data
-
Gene name
SKP2
- Application
-
Alternative Names
SKP2；FBXL1；S-phase kinase-associated Protein 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13309
-
Expression Region
1-424aa
-
AA Sequence
MHRKHLQEIPDLSSNVATSFTWGWDSSKTSELLSGMGVSALEKEEPDSEN IPQELLSNLGHPESPPRKRLKSKGSDKDFVIVRRPKLNRENFPGVSWDSL PDELLLGIFSCLCLPELLKVSGVCKRWYRLASDESLWQTLDLTGKNLHPD VTGRLLSQGVIAFRCPRSFMDQPLAEHFSPFRVQHMDLSNSVIEVSTLHG ILSQCSKLQNLSLEGLRLSDPIVNTLAKNSNLVRLNLSGCSGFSEFALQT LLSSCSRLDELNLSWCFDFTEKHVQVAVAHVSETITQLNLSGYRKNLQKS DLSTLVRRCPNLVHLDLSDSVMLKNDCFQEFFQLNYLQHLSLSRCYDIIP ETLLELGEIPTLKTLQVFGIVPDGTLQLLKEALPHLQINCSHFTTIARPT IGNKKNQEIWGIKCRLTLQKPSCL
-
Molecular Weight
73 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SKP2 (S-phase kinase-associated protein 2) is an E3 ubiquitin ligase known for its critical role in regulating the cell cycle and promoting oncogenic processes. It targets proteins such as p27Kip1 for ubiquitination, leading to their degradation and thereby facilitating cell cycle progression from the G1 to S phase. Overexpression of SKP2 has been implicated in various cancers, making it a potential biomarker for tumor progression and a target for therapeutic intervention. The study of recombinant SKP2 proteins has gained momentum as researchers seek to elucidate its precise mechanism of action and interactions with substrate proteins. Additionally, the production of SKP2 in a recombinant form allows for the investigation of its structural and functional properties in a controlled setting, providing insights that are essential for understanding its role in tumorigenesis. These studies can pave the way for the development of innovative cancer treatments aimed at modulating SKP2 activity, potentially inhibiting its function in cancer cells and restoring normal regulatory pathways in the cell cycle. Thus, the investigation of SKP2 recombinant proteins not only enhances our fundamental understanding of cell cycle regulation but also opens new avenues for cancer therapeutic strategies.
